Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 1 (2006), Issue 7 (July)

1. Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy.
   AIDS, 20(9): 1253-60. [Abstract] [Full-text]
2. Organizational change in management of hepatitis C: evaluation of a CME program.
   J Contin Educ Health Prof, 26(2): 145-60. [Abstract] [Full-text]
3. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis.
   Hepatology, 44(1): 85-90. [Abstract] [Full-text]
4. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses.
   Hepatology, 44(1): 126-39. [Abstract] [Full-text]
5. Hepatitis B virus genotype G monoinfection and its transmission by blood components.
   Hepatology, 44(1): 99-107. [Abstract] [Full-text]
6. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B.
   Hepatology, 44(1): 108-16. [Abstract] [Full-text]
7. Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis.
   Hepatology, 44(1): 216-27. [Abstract] [Full-text]
8. Different anti-HCV profiles of statins and their potential for combination therapy with interferon.
   Hepatology, 44(1): 117-25. [Abstract] [Full-text]
9. Anonymous pilot study of hepatitis C virus prevalence in liver transplant surgeons.
   Liver Transpl, 12(7): 1084-8. [Abstract] [Full-text]
10. Acquired hepatocerebral degeneration in a patient with HCV cirrhosis: complete resolution with subsequent recurrence after liver transplantation.
    Liver Transpl, 12(7): 1161-5. [Abstract] [Full-text]
11. The natural history of hepatitis C virus in pediatric liver transplant recipients.
    Liver Transpl, 12(7): 1119-23. [Abstract] [Full-text]
12. Active immunisation during an outbreak of hepatitis A in a German day-care centre.
    Vaccine, 24(29): 5684-9. [Abstract] [Full-text]
13. Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation.
    Liver Transpl, 12(7): 1104-11. [Abstract] [Full-text]
14. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity.
    Prog Neuropsychopharmacol Biol Psychiatry, 30(6): 1163-6. [Abstract] [Full-text]
15. Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.
    Liver Transpl, 12(7): 1067-76. [Abstract] [Full-text]
16. Identification of a specific gene expression pattern associated with HCV-induced pathogenesis in HCV- and HCV/HIV-infected individuals.
    Virology, 350(2): 453-64. [Abstract] [Full-text]
17. Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma.
    Cancer Lett, 239(1): 10-20. [Abstract] [Full-text]
18. Treatment of chronic hepatitis B in children.
    J Pediatr Gastroenterol Nutr, 43: S56-60. [Abstract] [Full-text]
19. Can donors with prior hepatitis be safely used for heart transplantation?
    J Heart Lung Transplant, 25(7): 805-13. [Abstract] [Full-text]
20. Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese.
    Aliment Pharmacol Ther, 23(12): 1703-11. [Abstract] [Full-text]
21. Study of IgG subclass profiles of anti-HBs in populations with different HBV infection status.
    Viral Immunol, 19(2): 277-84. [Abstract] [Full-text]
22. Influence of disease stage on polyethylenimine-mediated plasmid DNA delivery in murine hepatitis.
    Int J Pharm, 318(1): 139-45. [Abstract] [Full-text]
23. Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes.
    Gene Ther, 13(14): 1088-96. [Abstract] [Full-text]
24. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: a proof-of-concept study.
    Gene Ther, 13(14): 1110-7. [Abstract] [Full-text]
25. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
    J Infect, 53(1): 36-42. [Abstract] [Full-text]
26. Prevalence and clinical role of GBV-C infection after cardiac surgery in childhood: a study on 414 patients.
    J Infect, 53(1): 43-8. [Abstract] [Full-text]
27. Audit of hepatitis C antibody requests made by a genito-urinary department.
    Int J STD AIDS, 17(7): 482-3. [Abstract] [Full-text]
28. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis.
    Dig Dis Sci, 51(5): 968-75. [Abstract] [Full-text]
29. Quasispecies as predictive response factors for antiviral treatment in patients with chronic hepatitis C.
    Dig Dis Sci, 51(5): 960-7. [Abstract] [Full-text]
30. Successful treatment with novel triple drug combination consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegylated interferon therapy.
    Dig Dis Sci, 51(5): 956-9. [Abstract] [Full-text]
31. Effectiveness of a screening program for hepatitis C.
    Dig Dis Sci, 51(5): 976-81. [Abstract] [Full-text]
32. Viral hepatitis prevention by immunization.
    J Pediatr (Rio J), 82(3): S55-66. [Abstract] [Full-text]
33. Allergic hepatitis induced by drugs.
    Curr Opin Allergy Clin Immunol, 6(4): 258-65. [Abstract] [Full-text]
34. Lamivudine resistance of hepatitis B virus masked by coemergence of mutations in probe region of the COBAS AMPLICOR assay.
    J Clin Microbiol, 44(7): 2587-9. [Abstract] [Full-text]
35. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection.
    J Clin Microbiol, 44(7): 2507-11. [Abstract] [Full-text]
36. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Clin Transplant, 20(3): 369-73. [Abstract] [Full-text]
37. Reactivation of hepatitis and lamivudine therapy in 11 HBsAg-positive renal allograft recipients: a single centre experience.
    Clin Transplant, 20(3): 351-8. [Abstract] [Full-text]
38. Necrolytic acral erythema in Egyptian patients with hepatitis C virus infection.
    J Gastroenterol Hepatol, 21(7): 1200-6. [Abstract] [Full-text]
39. Randomized double blind placebo-controlled trial of a Chinese herbal therapy (CH100) in chronic hepatitis C.
    J Gastroenterol Hepatol, 21(7): 1184-8. [Abstract] [Full-text]
40. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
    J Gastroenterol Hepatol, 21(7): 1177-83. [Abstract] [Full-text]
41. Profile of chronic hepatitis B virus in children in India: experience with 116 children.
    J Gastroenterol Hepatol, 21(7): 1170-6. [Abstract] [Full-text]
42. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms.
    J Gastroenterol Hepatol, 21(7): 1163-9. [Abstract] [Full-text]
43. ANIT toxicity toward mouse hepatocytes in vivo is mediated primarily by neutrophils via CD18.
    Am J Physiol Gastrointest Liver Physiol, 291(2): G355-63. [Abstract] [Full-text]
44. Serum alanine aminotransferase level and response to interferon-ribavirin combination therapy in patients with chronic hepatitis C.
    J Coll Physicians Surg Pak, 16(7): 460-3. [Abstract] [Full-text]
45. Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipient on hemodialysis: a case report.
    Am J Transplant, 6(7): 1746-51. [Abstract] [Full-text]
46. Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B co-infection after liver transplantation.
    Am J Transplant, 6(7): 1600-8. [Abstract] [Full-text]
47. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis.
    Am J Transplant, 6(7): 1586-99. [Abstract] [Full-text]
48. Prevalence of mutations in hepatitis C virus core protein associated with alteration of NF-kappaB activation.
    Virus Res, 121(1): 51-7. [Abstract] [Full-text]
49. Does interferon improve portal hypertension?
    J Antimicrob Chemother, 58(1): 7-12. [Abstract] [Full-text]
50. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C.
    J Antimicrob Chemother, 58(1): 140-6. [Abstract] [Full-text]
51. Incidence of statin hepatotoxicity in patients with hepatitis C.
    Clin Gastroenterol Hepatol, 4(7): 902-7; quiz 806. [Abstract] [Full-text]
52. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis.
    Gastroenterology, 131(1): 179-93. [Abstract] [Full-text]
53. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity.
    Gastroenterology, 131(1): 165-78. [Abstract] [Full-text]
54. Clinical and therapeutic implications of hepatitis C virus compartmentalization.
    Gastroenterology, 131(1): 76-84. [Abstract] [Full-text]
55. Hepatopulmonary syndrome in patients with hypoxic hepatitis.
    Gastroenterology, 131(1): 69-75. [Abstract] [Full-text]
56. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy.
    Gastroenterology, 131(1): 59-68. [Abstract] [Full-text]
57. Preliminary results of HBV DNA testing of Polish haemophilia patients--lack of occult HBV infection.
    Haemophilia, 12(4): 380-3. [Abstract] [Full-text]
58. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy?
    Haemophilia, 12(4): 372-9. [Abstract] [Full-text]
59. Hepatitis C virus genotype and HIV coinfection affect cytokine mRNA levels in unstimulated PBMC but do not shift the T1/T2 balance.
    Immunol Cell Biol, 84(4): 390-5. [Abstract] [Full-text]
60. Surveillance of HIV and viral hepatitis by analysis of samples from drug related deaths.
    Eur J Epidemiol, 21(5): 383-7. [Abstract] [Full-text]
61. Decline in HCV testing and compliance with guidelines in patients of Sentinelles general practitioners, 1996-2002.
    Eur J Epidemiol, 21(5): 397-405. [Abstract] [Full-text]
62. Acute hepatitis B virus window-period blood donations detected by individual-donation nucleic acid testing: a report on the first two cases found and interdicted in Spain.
    Transfusion, 46(7): 1138-42. [Abstract] [Full-text]
63. Case finding for hepatitis C in primary care: a cost utility analysis.
    Fam Pract, 23(4): 393-406. [Abstract] [Full-text]
64. Analysis of CD28 and bcl-2 expression on peripheral blood and liver-infiltrating mononuclear cells in patients with autoimmune hepatitis.
    J Clin Immunol, 26(4): 323-30. [Abstract] [Full-text]
65. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies.
    Ann Rheum Dis, 65(8): 983-9. [Abstract] [Full-text]
66. Identification of a naturally occurring recombinant genotype 2/6 hepatitis C virus.
    J Virol, 80(15): 7569-77. [Abstract] [Full-text]
67. Thyroid disorders in chronic hepatitis C virus infection.
    Thyroid, 16(6): 563-72. [Abstract] [Full-text]
68. Intrahepatic gene expression in human alcoholic hepatitis.
    J Hepatol, 45(2): 306-20. [Abstract] [Full-text]
69. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).
    J Hepatol, 45(2): 204-13. [Abstract] [Full-text]
70. Alterations in the rat serum proteome during liver injury from acetaminophen exposure.
    J Pharmacol Exp Ther, 318(2): 792-802. [Abstract] [Full-text]
71. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study.
    J Hepatol, 45(2): 197-203. [Abstract] [Full-text]
72. Enhanced ability of peripheral invariant natural killer T cells to produce IL-13 in chronic hepatitis C virus infection.
    J Hepatol, 45(2): 190-6. [Abstract] [Full-text]
73. Analysis of intrahepatic HBV-specific cytotoxic T-cells during and after acute HBV infection in humans.
    J Hepatol, 45(2): 182-9. [Abstract] [Full-text]
74. Differential antigenic hierarchy associated with spontaneous recovery from hepatitis C virus infection: implications for vaccine design.
    J Infect Dis, 194(4): 454-63. [Abstract] [Full-text]
75. GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype.
    J Infect Dis, 194(4): 410-9. [Abstract] [Full-text]
76. Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following orthotopic liver transplantation: effective prophylaxis against recurrence.
    Clin Transplant, 20(4): 524-5. [Abstract] [Full-text]
77. Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome.
    Clin Transplant, 20(4): 465-70. [Abstract] [Full-text]
78. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
    J Viral Hepat, 13(6): 409-14. [Abstract] [Full-text]
79. Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients.
    J Viral Hepat, 13(6): 402-8. [Abstract] [Full-text]
80. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
    J Viral Hepat, 13(6): 396-401. [Abstract] [Full-text]
81. Overlap lamivudine treatment in patients with chronic hepatitis B receiving adefovir for lamivudine-resistant viral mutants.
    J Viral Hepat, 13(6): 387-95. [Abstract] [Full-text]
82. The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase.
    J Viral Hepat, 13(6): 377-86. [Abstract] [Full-text]
83. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response.
    J Viral Hepat, 13(6): 371-6. [Abstract] [Full-text]
84. Non-invasive models for predicting histology in patients with chronic hepatitis B.
    Liver Int, 26(6): 666-72. [Abstract] [Full-text]
85. High prevalence of infection with a single hepatitis C virus genotype in a small rural community of Argentina.
    Liver Int, 26(6): 660-5. [Abstract] [Full-text]
86. Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.
    Liver Int, 26(6): 650-9. [Abstract] [Full-text]
87. Hepatitis C infection in Alaska Natives with persistently normal, persistently elevated or fluctuating alanine aminotransferase levels.
    Liver Int, 26(6): 643-9. [Abstract] [Full-text]
88. Distribution of hepatitis B virus genotypes among patients with chronic infection.
    Liver Int, 26(6): 636-42. [Abstract] [Full-text]
89. Synthesis of 2-C-hydroxymethylribofuranosylpurines as potent anti-hepatitis C virus (HCV) agents.
    Bioorg Med Chem Lett, 16(16): 4190-4. [Abstract] [Full-text]
90. Y-40138, a multiple cytokine production modulator, protects against D-galactosamine and lipopolysaccharide-induced hepatitis.
    Life Sci, 79(9): 822-7. [Abstract] [Full-text]
91. DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected hepatocytes and protect ducks against the development of chronic infection in a virus dose-dependent manner.
    Virology, 351(1): 159-69. [Abstract] [Full-text]
92. The prevalence of HCV antibody in South Australian prisoners.
    J Infect, 53(2): 125-30. [Abstract] [Full-text]
93. Analysis of human and swine hepatitis E virus (HEV) isolates of genotype 3 in Japan that are only 81-83 % similar to reported HEV isolates of the same genotype over the entire genome.
    J Gen Virol, 87: 2363-9. [Abstract] [Full-text]
94. Viral hepatitis and liver transplantation.
    Semin Liver Dis, 26(3): 285-97. [Abstract] [Full-text]
95. Study on hepatitis B virus pre-S/S gene mutations of renal tissues in children with hepatitis B virus-associated membranous nephropathy.
    Pediatr Nephrol, 21(8): 1097-103. [Abstract] [Full-text]
96. Hepatitis B virus genotypes among the Jarawas: a primitive Negrito tribe of Andaman and Nicobar Islands, India.
    Arch Virol, 151(8): 1499-510. [Abstract] [Full-text]
97. Higher clearance of hepatitis C virus infection in females compared with males.
    Gut, 55(8): 1183-7. [Abstract] [Full-text]
98. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies.
    Gut, 55(8): 1188-96. [Abstract] [Full-text]
99. Effects of interferon plus ribavirin treatment on NF-kappaB, TGF-beta1, and metalloproteinase activity in chronic hepatitis C.
    Mod Pathol, 19(8): 1047-54. [Abstract] [Full-text]
100. Fatal liver disease despite sustained eradication of recurrent hepatitis C virus requiring liver retransplantation.
     Transplantation, 82(2): 286-8. [Abstract] [Full-text]
101. Hepatitis C viral recurrence in a pediatric patient following liver transplantation.
     Pediatr Transplant, 10(5): 617-22. [Abstract] [Full-text]
102. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma.
     APMIS, 114(6): 420-7. [Abstract] [Full-text]
103. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched.
     Epidemiol Rev, 28: 126-35. [Abstract] [Full-text]
104. Hepatitis A in the era of vaccination.
     Epidemiol Rev, 28: 101-11. [Abstract] [Full-text]
105. Hepatitis B virus infection: epidemiology and vaccination.
     Epidemiol Rev, 28: 112-25. [Abstract] [Full-text]
106. Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin.
     Transplantation, 82(1): 43-7. [Abstract] [Full-text]
107. CT Evaluation of the progression of hypoattenuating nodular lesions in virus-related chronic liver disease.
     AJR Am J Roentgenol, 187(2): 454-63. [Abstract] [Full-text]
108. Severe hepatotoxicity after therapeutic doses of acetaminophen.
     Clin Ther, 28(5): 755-60. [Abstract] [Full-text]
109. Role of innate immunity in acetaminophen-induced hepatotoxicity.
     Expert Opin Drug Metab Toxicol, 2(4): 493-503. [Abstract] [Full-text]
110. Identification of hepatitis B virus subgenotype A3 in rural Gabon.
     J Med Virol, 78(9): 1175-84. [Abstract] [Full-text]
111. Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.
     J Med Virol, 78(9): 1190-7. [Abstract] [Full-text]
112. HCV-related morbidity in a rural community of Egypt.
     J Med Virol, 78(9): 1185-9. [Abstract] [Full-text]
113. Phylogenetic relatedness and genetic diversity of hepatitis B virus isolates in Eastern India.
     J Med Virol, 78(9): 1164-74. [Abstract] [Full-text]
114. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
     J Clin Virol, 36(4): 283-91. [Abstract] [Full-text]
115. Dynamics of CD81 expression on lymphocyte subsets during interferon-alpha-based antiviral treatment of patients with chronic hepatitis C.
     J Leukoc Biol, 80(2): 298-308. [Abstract] [Full-text]
116. High-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
     Life Sci, 79(11): 1100-7. [Abstract] [Full-text]
117. Neuropsychiatric complications after liver transplantation: role of immunosuppression and hepatitis C.
     Dig Dis Sci, 51(6): 1079-81. [Abstract] [Full-text]
118. Occupational manganese neurotoxicity provoked by hepatitis C.
     Neurology, 67(2): 322-3. [Abstract] [Full-text]
119. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B.
     Am J Gastroenterol, 101(7): 1516-23. [Abstract] [Full-text]
120. Contributions to hepatic fibrosis in HIV-HCV coinfected and HCV monoinfected patients.
     Am J Gastroenterol, 101(7): 1509-15. [Abstract] [Full-text]
121. Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis.
     Am J Gastroenterol, 101(7): 1490-6. [Abstract] [Full-text]
122. Neurocognitive functioning and HAART in HIV and hepatitis C virus co-infection.
     AIDS, 20(12): 1591-5. [Abstract] [Full-text]
123. The role of pathology in the identification of drug-induced hepatic toxicity.
     Expert Opin Drug Metab Toxicol, 2(2): 241-7. [Abstract] [Full-text]
124. Relationships between hepatitis C virus replication and CXCL-8 production in vitro.
     J Virol, 80(16): 7885-93. [Abstract] [Full-text]
125. Effect of leptin administration on membrane-bound adenosine triphosphatase activity in ethanol-induced experimental liver toxicity.
     J Pharm Pharmacol, 58(8): 1113-9. [Abstract] [Full-text]
126. Alpha-tocopherol [corrected] and ascorbic acid attenuates the ribavirin [corrected] induced decrease of eicosapentaenoic acid in erythrocyte membrane in chronic hepatitis C patients.
     J Gastroenterol Hepatol, 21(8): 1269-75. [Abstract] [Full-text]
127. Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis.
     J Gastroenterol Hepatol, 21(8): 1266-8. [Abstract] [Full-text]
128. Steatosis in chronic hepatitis C: relationship to the virus and host risk factors.
     J Gastroenterol Hepatol, 21(8): 1236-9. [Abstract] [Full-text]
129. Performance of a new-generation chemiluminescent assay for hepatitis B surface antigen.
     Clin Chem, 52(8): 1592-8. [Abstract] [Full-text]
130. Evaluation of cardiac function by tissue Doppler imaging in children with chronic hepatitis.
     J Pediatr Gastroenterol Nutr, 43(2): 222-7. [Abstract] [Full-text]
131. Hepatitis C in children: a quaternary referral center perspective.
     J Pediatr Gastroenterol Nutr, 43(2): 209-16. [Abstract] [Full-text]
132. Behavioural predictors of subsequent hepatitis C diagnosis in a UK clinic sample of HIV positive men who have sex with men.
     Sex Transm Infect, 82(4): 298-300. [Abstract] [Full-text]
133. Hepatitis induced by Noni juice from Morinda citrifolia: a rare cause of hepatotoxicity or the tip of the iceberg?
     Digestion, 73(2): 167-70. [Abstract] [Full-text]
134. Anticoagulation and inhibition of nitric oxide synthase influence hepatic hypoxia after monocrotaline exposure.
     Toxicology, 225(2): 128-37. [Abstract] [Full-text]
135. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
     BMC Infect Dis, 6: 93. [Abstract] [Full-text]

© 2006-2010 Hepatitis Research Today. All Rights Reserved.